article thumbnail

The next phase of the multiomics evolution, powered by AI

Drug Target Review

In drug discovery, where reproducibility, sensitivity and sample-limited contexts are paramount, these challenges pose significant barriers. Integrated multiomics is the future The impact on drug development could be profound. Even when great care is taken, data produced under separate workflows cannot always be effectively reconciled.

RNA 72
article thumbnail

Assembling data sets for training ML bioactivity models

Molecular Design

However, the term 'QSAR' does appears to be less used these days, possibly reflecting the limited impact that QSAR approaches have made on real world drug discovery, and it's also much easier to persuade people that you're doing artificial intelligence (AI) if you describe your QSAR models as ML models.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

A Legacy of Collaborative Excellence The relationship between Bayer and Tsinghua University began in 2009 as part of a broader effort by Bayer to establish strong academic linkages in Asia’s rapidly advancing research landscape.

article thumbnail

Gepirone

New Drug Approvals

4] This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness. [5] 5] It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009.

FDA 62
article thumbnail

Elacestrant 

New Drug Approvals

Food and Drug Administration (FDA). “RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models” Anti-Cancer Drugs. 1] [4] It is taken by mouth. [1] 3] [7] PATENTS Cruskie MP, et al. Retrieved 11 February 2023. 27 January 2023.

FDA 62
article thumbnail

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Drug Patent Watch

Lessons from Past Pharmaceutical Negotiations Case Study: Merck and Schering-Plough Merger The 2009 merger between Merck and Schering-Plough, valued at $41.1 These agreements tie a drug’s price to its real-world performance, aligning the interests of manufacturers, payers, and patients.

article thumbnail

A global push for better animal welfare in research

Drug Target Review

Liz Nunamaker, Executive Director of Global Animal Welfare at Charles River , is leading efforts to embed welfare, integrity and the 3Rs – replacement, reduction and refinement – into the heart of drug discovery and development. For now, we need all these models working together to ensure drug safety.”